Coronavirus patients who are receiving an experimental drug called Remdesivir have been recovering quickly, with most going back home in a few days.

The patients taking part in a clinical examination of the drug have all has severe respiratory symptoms and fever, but were discharged from the hospital after less than a week of treatment.

"The best news is that most of our patients have already been discharged, which is great. We've only had two patients perish," Dr. Kathleen Mullane, an infectious disease specialist at the University of Chicago who is leading the clinical trial said.

Dr Mullane did not immediately respond to a request for comment from CNN. The university said it would comment once the official results of the examination were ready.

There is no approved therapy for the Coronavirus disease, which causes severe pneumonia and acute respiratory anguish in some patients. However, the National Institutes of Health is Organising trials of several drugs, among them is Remdesivir.

The drug made by Gilead Sciences, was tested against Ebola but had very little success in terms of result, but multiple studies in animals showed the drug could prevent and treat Coronaviruses associated with Severe Acute Respiratory Syndrome (SARS) and Middle East Respiratory Syndrome (MERS). It is imperative to note that in February, the World Health Organisation (WHO) said Remdesivir showed potential against COVID-19. 

"Most of our patients are severe and most of them are leaving at six days, so that tells us duration of therapy doesn't have to be 10 days,” Dr Mullane was quoted as saying.

Although, the examination does not include what known as a control group, so it will be difficult to predict whether the drug is truly helping patients recover better. With a control arm, some patients do not receive the drug being tested so that doctors can determine whether it’s the drug that is really affecting their condition.

Trials of the drug are ongoing at several other clinical centers as well. Gilead is sponsoring tests of the drug in 2,400 patients with severe COVID-19 symptoms in 152 trial sites, and 1,600 patients with moderate symptoms in 169 trial sites. 

"We understand the urgent need for a COVID-19 treatment and the resulting interest in data on our investigational antiviral drug Remdesivir," the company said in a statement to CNN. But it said a few stories about patients are just that -- stories.

"The totality of the data needs to be analysed in order to draw any conclusions from the trial. Anecdotal reports, while encouraging, do not provide the statistical power necessary to determine the safety and efficacy profile of Remdesivir as a treatment for Covid-19," Gilead said.